

National Issues

- CMS actions with a "hard stop" at 90 MME's in 2019?
- DEA reducing manufacturing of opioids 25% in 2017 and a further 20% in 2018 and more in 2019
- Pharmacy chains and insurance payors with varying policies
- Numerous states capping at <90-100 MME's
- Numerous laws regarding initial prescriptions
- Oregon initiative
- Increased investigations of providers and pharmacies

Opioid Deaths


- Major reason for CDC, national and state legislative involvement
- 72,000 overdose deaths in 2017
- Significant escalation in illicit opioids
- Diversion: most deaths are from "non-prescribed" opioids
- Lethal combinations especially with benzodiazepines
- Illegal opioids outpacing prescribed opioids
- Without question the number one reason for governmental intrusion

CDC Enhanced Opioid Overdose Surveillance 2017

- 11 states participated including Oklahoma
- 59% of deaths due to illicit opioids
- 18.5% combined prescription and illicit opioids
- 18% positive for only prescription opioids
 - 50% of these deaths also positive for benzodiazepine
- "Findings indicate that illicit opioids were a major driver of deaths... and were detected in approximately three of four deaths"

Prescription Opioid Reduction

Prescription Opioid Analgesics



Source Where Respondent Obtained




Figure 10. Percent Change in Predicted 12 Month-ending Count of Drug Overdose Deaths, by Jurisdiction: January 2017 to January 2018



Legend for Percent Change in Drug Overdose Deaths Between 12 Month Ending Periods

Are Opioids Efficacious for Chronic Pain?

- Long term outcome studies are lacking but also lacking for most all pain therapies
- Insight based on available evidence
 - Opioid use may be the most important factor impeding recovery of function
 - Opioids may not consistently and reliably relieve pain and can decrease quality of life
 - The routine use of opioids cannot be recommended
- Appropriate only for selected patients with moderate-severe pain that significantly affects quality of life

First Line Approach

- Important issue in SB1446
- Non-pharmacological approach
- Non-opioid approach
- Emphasis on
 - Behavioral therapies
 - Functional therapies
 - Adjunctive medications
 - Opioids are a "last resort" option

Chronic Opioid Therapy (COT)

- Consensus agreement that it can be useful in carefully selected patients with moderate to severe pain
- SB1446 demands constant attention to attempts at lowering doses
- Absolutely demands:
 - Compliance: As with any medical problem
 - Documentation
 - Vigilant monitoring for abuse and diversion
 - Assessment of opioid related side effects
 - Understanding of opioid use in chronic pain

Patient Selection and Risk Stratification

- History, physical examination and diagnostic testing
- Psychosocial risk assessment
- Expectations: physician and patient
- Risk assessment is an underdeveloped skill for most clinicians
- SB1446 requires vigilant monitoring of abuse and addiction
- SB1446 emphasizes documentation of the progress of the patient to the treatment objectives

The "Ideal" Patient

- Well defined pathology
- Good insight and desire to improve
- Willing to "work hard" to improve
- Interested in other modalities and work-up
- Not focused on opioids but desire to improve
- Good understanding that opioids will provide "some" relief to help them improve
- Examples

The "Wrong" Patient

- Diffuse and poorly localized pain
- No interest in work-up or other modalities
- Focus is on opioids alone
- Poor insight and unrealistic expectations
- Poorly motivated with no desire to "work hard"
- Poor functionality
- Examples

Patients at Risk

- Psychosocial issues
- History of addiction
 - Risk of relapse, harm and treatment failure
- Adverse Childhood Experience (ACE)
 - Abuse, neglect, household dysfunction and traumatic stressors
- Poor motivation and lack of insight
- Disability, Medicaid and even prior criminal activity
- Unrealistic expectations
- Prior overdose

Opioid Use Disorder

- 3-26% incidence
- Significant impairment or distress
- Poor insight and social support
- Inability to reduce opioids
- Inability to control use
- Decreased function
- Social function reduced
- Failure to fulfill work, home or school obligations
- Commonly referred to as "abuse" in the literature

Medication Assisted Treatment

- Emphasized with patients who display OUD
- Buprenorphine: Partial agonist
- Methadone
- Behavioral therapies
 - Help maintain retention
 - Help reduce relapse rate
- CDC emphasis on:
 - Availability
 - Cost

Opioid Induced Hyperalgesia

- Increased sensitivity to noxious or non-noxious stimuli
- Sensitization of pro-nociceptive mechanisms
- Hypersensitivity and allodynia
- Confused with tolerance
- Caused with rapid escalation and high dose therapy?
- Activity at the NMDA receptor in dorsal horn
- Novel medications now and future

“Forced” Dose Reductions

- There is really no evidence on this approach
- A vulnerable population of patients
- Does this lead to more harm?
- Rupture of patient-physician relationship
- Increased disability
- Risk of illicit drug use
- Suicide
- Consider referral

SB1446: Major Points of Emphasis

- Addiction and abuse
- Dose reduction and cessation
- Emphasis on lower MME's
- Alternative therapies
- Strong focus decreasing the risks of acute pain leading to chronic opioid therapy
- ***Strong language for assessing, documenting and specifying your care of the opioid patient***

Required CME

- One hour per year
- Pain management and opioid use or
- Addiction medicine

Initial 7 Day Prescription

- Acute pain in an opioid naïve patient
- Acute pain episode due to surgery or new condition in a patient on opioids. Examples:
 - Dental procedure
 - Renal stone
 - ER visit for unrelated pain complain
- Shall be for the lowest effective dose
- Must check PMP
- Failure to check PMP shall be grounds for discipline

Initial 7 Day Prescription

- Take and **document** a thorough medical history
- Including experience of the patient with non-opioid medication and non-pharmacological pain management
- Screen for substance abuse and addiction
- Conduct and **document** a physical examination
- PPA required for under 18 and pregnancy

Prior to Issuing an Initial Prescription

- Practitioner shall discuss and **document** with a note in medical record of the risks not limited to
 - Risks of addiction and overdose and risks of combining alcohol and or benzodiazepines
 - The reasons why the prescription is necessary
 - Alternative treatments that may be available
 - Risks associated with the drug being prescribed such as physical and psychological dependence, that "opioids are highly addictive" and overutilization can lead to death

Subsequent 7 Day Prescription

- Practitioner determines that the prescription is necessary
- **Document** rational for subsequent prescription
- Practitioner determines the the subsequent script does not present a risk of abuse, addiction or diversion and **documents** in the chart
- Refills? 14 day supply at initial prescription?
- Sequential prescriptions?
- In office visit with the practitioner?

Prior to Issuing a 3rd Prescription

- Similar to issuing the initial prescription
- Practitioner shall discuss and **document** with a note in medical record of the risks not limited to
 - Risks of addiction and overdose and risks of combining alcohol and or benzodiazepines
 - The reasons why the prescription is necessary
 - Alternative treatments that may be available
 - Risks associated with the drug being prescribed such as physical and psychological dependence, that "opioids are highly addictive" and overutilization can lead to death

Patient-Provider Agreement

- Provides informed consent
- Essentially an opioid "contract"
- Needed before the 3rd prescription and for chronic pain treatment
- Needed at initial prescription for under 18 and pregnancy
- The Boards will provide an approved agreement for use

Patient-Provider Agreement

- Explain the possible risks
- Document the understanding of patient and physician
- Establish the rights and obligations of the patient
- Storage of opioids
- Establish specific medications and other treatments
- Specify the measures used by the physician to monitor the patient
- Delineate the process for termination of agreement
- Compliance shall constitute valid informed consent

Issuance of a 3rd Prescription

- The practitioner shall enter into a patient-provider agreement (PPA)
- The practitioner shall include a note in the medical record that the patient has discussed with the practitioner the risks of developing physical or psychological dependence
- Alternative therapies that may be available and...
- **Document in the medical record**
- Remember...
 - PPA needed initially for under 18 and pregnancy

Chronic Utilization of Opioids

- When an opioid is continuously prescribed for 3 months or more the practitioner shall
 - Assess patient prior to every renewal to determine if the patient is experiencing problems with physical or psychological dependence *and document* the results of that assessment
 - What constitutes assessment?
 - In office? By phone? Telemedicine?
 - Refills of Schedule III?
 - Mid level providers?
 - "The" practitioner

Chronic Utilization of Opioids

- Review at a minimum every 3 months
 - The course of treatment
 - Any new information about the etiology of the pain
 - Progress of the patient toward treatment objectives
 - Monitor the compliance with the pain management agreement and any recommendations that the patient seek a referral
 - Check PMP (and save in the chart?)
 - **Document the results**

Chronic Utilization of Opioids

- Periodically make reasonable efforts, "*unless clinically contraindicated*", to
 - Stop use of controlled substance
 - Attempts to decrease the dosage
 - Try other medications and treatment modalities in an effort to reduce the potential for abuse or development of physical or psychological dependence
 - DOCUMENT and SPECIFY the efforts undertaken

Further Requirements

- “Any provider authorized to prescribe opioids shall adopt and maintain a written policy or policies that include execution of a written agreement to engage in an informed consent process between the prescribing provider and “qualifying opioid therapy patient”.
- PPA in combination with written policy

Qualifying Opioid Therapy Patient

- **A patient requiring opioid treatment for more than 3 months**
 - Does not matter if low dose or high dose
- **A patient who is prescribed a benzodiazepine and opioid together**
 - What about different doctors prescribing each?
 - Psychiatrist and PCP
- **A patient prescribed a dose of opioids over 100 MME's**

The OBNDD is Authorized To....

- Provide unsolicited notification to the licensing board
 - If a patient has received one or more prescriptions for CDS in quantities or frequency inconsistent with recognized standards or safe practice
 - If a practitioner has exhibited prescriptive behavior indicating potentially problematic prescribing patterns
 - Failure to check PMP as required under law shall be grounds for licensing board to take disciplinary action

OBNDD Shall Report:

- Registration of prescribers and dispensers in the central repository (PMP)
- Data regarding the checking and using of the PMP
- Data from boards regarding continuing education
- Effects on the prescriber work force
- Changes in the number of patients taking more than 100 MME's
- Data regarding quantity of opioid medications prescribed in MME's

Further Points

- Shall not apply to patients with active cancer pain, end of life, palliative, hospice care or long term care facility
- Shall not apply to medications for the treatment of substance abuse or opioid dependence
- "The provider shall be held harmless from civil litigation for failure to treat pain if the event occurs because of the non-adherence by the patient with any of the provisions in the patient-provider agreement".

Conclusion: Key Points

- SB1446 has stringent documentation requirements
- Much emphasis placed on addiction and abuse
- Focus on alternatives to opioids
- Consider weaning or decreasing dosages even in well functioning patients
- Attempts to decrease acute pain episodes leading to chronic opioid therapy
- Many unanswered questions
